Subgroup analysis of the PANORAMA 1 trial of panobinostat for multiple myeloma

At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, discusses the results of a predefined subgroup analysis of the PANORAMA 1 trial, which evaluated the histone deacetylase inhibitor, panobinostat, plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and lenalidomide or thalidomide.

Share this video  
12th June 2015